The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

Predictive analytics forecast demand ... patients on PrEP, streamline operations, and capture every eligible prescription, 340bWell aims to play a critical role in reducing new HIV infections ...

A New Movement Calls for Change Women are being overlooked in the UK’s HIV response and face multiple barriers to prevention, testing, and care.In England, HIV diagnoses among women who have sex with ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

The Motley Fool. DATE Thursday, Apr 24, 2025 Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS Daniel O'Day: Chairman and Chief ...

In the meantime, we continue to expect robust demand led volume growth ... plans or expectations for the Len for PrEP launch or adversely affect our HIV business. Obviously, we're staying very ...

which shows the demand in the market for alternatives to daily oral PrEP. PrEP – generally used by at-risk people such as an HIV-negative individual with an HIV-positive partner – requires ...

The FDA said that PrEP – used to protect at-risk people such as an HIV-negative individual with ... which suggests it is expecting high demand for the injectable alternative.

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.